Subcutaneous unfractionated heparin compared with low-molecular-weight heparin for the initial treatment of venous thromboembolism

Current Opinion in Pulmonary Medicine

Volumn 11, Issue 5, 2005, Pages 363-367

  Bernardi, Enrico ^a,b   Prandoni, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Cost effectiveness; Home treatment; Low molecular weight heparin; Subcutaneous unfractionated heparin; Venous thromboembolism

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ALGORITHM; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; PARTIAL THROMBOPLASTIN TIME; PATIENT CARE; REVIEW; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 24744431851     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000174228.47725.79     Document Type: Review

References (25)

1. Büller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2004; 126:4013-4283. This comprehensive qualitative evidence-based review provides full-range recommendations for a rational approach to the treatment of patients with venous thromboembolism.
2. Siragusa S, Cosmi B, Piovella F, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100:269-277.
3. Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130:800-809.
4. Rocha E, Martinez-Gonzalez MA, Montes R, Panizo C. Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis. Haematologica 2000; 85:935-942.
5. Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160:181-188.
6. van den Belt AGM, Prins MH, Lensing AWA, et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd. This quantitative meta-analysis of published randomized clinical trials is based on strict methodologic criteria but is comprehensive and balanced.
7. Krishnan JA, Segal JB, Streiff MB, et al. Treatment of venous thromboembolism with low-molecular-weight heparin: a synthesis of the evidence published in systematic literature reviews. Respir Med 2004; 98:376-386. This is a critical review of the available meta-evidence, with its limitations and advantages.
8. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin. Chest 2004; 126:1888-2038.
9. Raschke R, Hirsh J, Guidry JR. Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med 2003; 138:720-723.
10. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154:49-56.
11. Hull RD, Raskob GE, Brant RF, et al. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy: the emerging theme of delayed recurrence. Arch Intern Med 1997; 157:2317-2321.
12. Hull RD, Raskob GE, Brant RF, et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for DVT. Arch Intern Med 1997; 157:2562-2568.
13. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315:1109-1114.
14. Bernardi E, Piccioli A, Oliboni G, et al. Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism: an overview. Thromb Haemost 2000; 84:22-26.
15. Arcelus JI, Caprini JA, Monreal M, et al. The management and outcome of acute venous thromboembolism: a prospective registry including 4011 patients. J Vasc Surg 2003; 38:916-922.
16. Hirsch DR, Lee TH, Morrison RB, et al. Shortened hospitalization by means of adjusted-dose subcutaneous heparin for deep venous thrombosis. Am Heart J 1996; 131:276-280.
17. Hommes DW, Bura A, Mazzolai L, et al. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of DVT: a meta-analysis. Ann Intern Med 1992; 116:279-284.
18. Prandoni P, Bagatella P, Bernardi E, et al. Use of an algorithm for administering subcutaneous heparin in the treatment of deep venous thrombosis. Ann Intern Med 1998; 129:299-302.
19. Kearon C, Harrison L, Crowther M, Ginsberg JS. Optimal dosing of subcutaneous heparin for the treatment of DVT. Thromb Res 2000; 97:395-403.
20. Anand SS, Bates S, Ginsberg JS, et al. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med 1999; 27:2029-2032.
21. Faivre R, Neuhart Y, Kieffer Y, et al. Un nouveau traitement des thromboses veineuses profondes: les fractions d'héparine de bas poids moleculaire: etude randomisee. Presse Med 1988; 17:197-200.
22. Lopaciuk S, Meissner AJ, Filipecki S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of DVT: a Polish multicenter trial. Thromb Haemost 1992; 68:14-18.
23. Belcaro G, Nicolaides AN, Cesarone MR, et al. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis. Angiology 1999; 50:781-787.
24. Prandoni P, Carnovali M, Marchiori A, for the Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med 2004; 164:1077-1083. This landmark study explores the potential of subcutaneous adjusted UFH for the treatment of a broad spectrum of patients with VTE in a randomized context against LMWH.
25. Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs. Chest 2004; 126:265S-286S.